CBLL

CeriBell, Inc. Common Stock

11.44 USD
-0.62
5.14%
At close Aug 25, 4:00 PM EDT
After hours
11.44
+0.00
0.00%
1 day
-5.14%
5 days
-6.23%
1 month
-24.39%
3 months
-33.80%
6 months
-55.21%
Year to date
-55.76%
1 year
-54.24%
5 years
-54.24%
10 years
-54.24%
 

About: CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Employees: 281

0
Funds holding %
of 7,428 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

264% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 11

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

8% more funds holding

Funds holding: 86 [Q1] → 93 (+7) [Q2]

4.43% more ownership

Funds ownership: 67.17% [Q1] → 71.61% (+4.43%) [Q2]

5% more capital invested

Capital invested by funds: $463M [Q1] → $485M (+$21.7M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for CBLL.

Financial journalist opinion

Based on 3 articles about CBLL published over the past 30 days

Positive
The Motley Fool
2 weeks ago
CeriBell (CBLL) Q2 Revenue Jumps 38%
CeriBell (CBLL) Q2 Revenue Jumps 38%
CeriBell (CBLL) Q2 Revenue Jumps 38%
Neutral
Seeking Alpha
2 weeks ago
CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Scott Blumberg - Chief Financial Officer Xingjuan Chao - Co-Founder, President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joshua Thomas Jennings - TD Cowen, Research Division Marie Yoko Thibault - BTIG, LLC, Research Division Robert Justin Marcus - JPMorgan Chase & Co, Research Division Travis Lee Steed - BofA Securities, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Brian Johnston - Gilmartin Group LLC Operator Ladies and gentlemen, thank you for standing by.
CeriBell, Inc. (CBLL) Q2 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Ceribell Reports Second Quarter 2025 Financial Results
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025.
Ceribell Reports Second Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
SUNNYVALE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Tuesday, August 5, 2025.
Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025
Neutral
GlobeNewsWire
1 month ago
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology Complaints Assert Infringement of Patents Related to Point-of-Care Electroencephalography (EEG) Technology
Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware
Neutral
GlobeNewsWire
3 months ago
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
Neutral
Seeking Alpha
3 months ago
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q1 2025 Earnings Call.
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Ceribell Reports First Quarter 2025 Financial Results
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.
Ceribell Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
3 months ago
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
Neutral
GlobeNewsWire
3 months ago
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP® (Federal Risk and Authorization Management Program) High authorization from the U.S. government.
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Charts implemented using Lightweight Charts™